Publicaciones en las que colabora con Jesús Egido de los Ríos (11)

2017

  1. Increased galectin-3 levels are associated with abdominal aortic aneurysm progression and inhibition of galectin-3 decreases elastase-induced AAA development

    Clinical Science, Vol. 131, Núm. 22, pp. 2707-2719

2014

  1. From tissue iron retention to low systemic haemoglobin levels, new pathophysiological biomarkers of human abdominal aortic aneurysm

    Thrombosis and Haemostasis, Vol. 112, Núm. 1, pp. 87-95

2013

  1. Statin use in aortic aneurismal disease to prevent progression and cardiovascular events: Review of experimental and clinical data

    Current Vascular Pharmacology, Vol. 11, Núm. 3, pp. 299-304

2012

  1. Increased plasma levels of NGAL, a marker of neutrophil activation, in patients with abdominal aortic aneurysm

    Atherosclerosis, Vol. 220, Núm. 2, pp. 552-556

2011

  1. Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms

    Atherosclerosis, Vol. 214, Núm. 2, pp. 486-489

2010

  1. Increased levels of thioredoxin in patients with abdominal aortic aneurysms (AAAs). A potential link of oxidative stress with AAA evolution

    Atherosclerosis, Vol. 212, Núm. 1, pp. 333-338

2009

  1. Biomarkers in Cardiovascular Medicine

    Revista Espanola de Cardiologia, Vol. 62, Núm. 6, pp. 677-688

2008

  1. Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis

    Kidney International

2006

  1. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: Potential implications for plaque stabilization

    Journal of Cardiovascular Pharmacology, Vol. 47, Núm. 1, pp. 60-69

  2. Modulación mediante tratamiento con atorvastatina y/o amlodipino del perfil de proteínas liberadas por placas ateroscleróticas humanas

    Clínica e investigación en arteriosclerosis, Vol. 18, Núm. 5, pp. 167-175

2005

  1. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month

    Stroke, Vol. 36, Núm. 8, pp. 1796-1800